Simon Schwartz Navarro Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools. Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca Cap de Secció Bioquímica Serveis transversals LinkedIn Twitter Orcid Email Simon Schwartz Navarro LinkedIn Twitter Orcid Email Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca Cap de Secció Bioquímica Serveis transversals Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.
Currently acting as Strategy director of biobanking and bioresources at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 40, with more that 115 high impact publications and 17 transferred patents. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM.
Proyectos Liberación dirigida de nanoconjugados de inhibidor de Alox5 contra células madre tumorales IP: Simon Schwartz Navarro Colaboradores: Laura García Latorre, Diana Fernandes de Rafael Entidad financiadora: Instituto de Salud Carlos III Financiación: 171215 Referencia: PI14/02079 Duración: 01/01/2015 - 31/12/2017 Sistemas de liberación farmacológica dirigidos contra células madre tumorales- prueba de concepto IP: Simon Schwartz Navarro Colaboradores: Joaquin Seras Franzoso, Miriam Izquierdo Sans Entidad financiadora: Asociación Española Contra el Cáncer Financiación: 135000 Referencia: 2014/AECC-AIO/SERAS Duración: 01/02/2015 - 31/01/2020 Targetting Combined Therapy to Cancer Stem Cells (NANOSTEM) IP: Simon Schwartz Navarro Colaboradores: Laura García Latorre Entidad financiadora: Instituto de Salud Carlos III Financiación: 145540.01 Referencia: PI11/01079 Duración: 01/01/2012 - 31/12/2014 Advancing on drug delivery-combined targeted treatments against human breast cancer and Leukemia (Oncotarget/Nano) IP: Simon Schwartz Navarro Colaboradores: Advancing on drug delivery-combined targeted treatments against human breast cancer and Leukemia (Oncotarget/Nano), Advancing on drug delivery-combined targeted treatments against human breast cancer and Leukemia (Oncotarget/Nano) Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN Financiación: 28300 Referencia: EUI2008-0170 Duración: 01/03/2009 - 01/03/2011 Paginación Primera página « Página anterior ‹ … Página 4 Página 5 Página actual 6 Página 7 Página 8 … Siguiente página › Última página »
